Loading
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Latest quote
$0.1796
−$0.0032 · -1.75%
After-hours
$0.1819
+$0.0023 · +1.28%
Oct 8, 6:38 PM ET
Regular session · ET · Market data may be delayed.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Day range
Current $0.1796
52-week range
Current $0.1796
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
17
Overpriced
Sentiment
50
Mixed
Risk
70
High Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
Day range
Current $0.1796
52-week range
Current $0.1796
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 88K USD | 170K USD | 202K USD | 141K USD | 135K USD |
| Cost of goods sold | 338K USD | 31K USD | 42K USD | — | 850K USD |
| Gross profit | −250K USD | 139K USD | 160K USD | 141K USD | −715K USD |
| Research and development | 3.92M USD | 6.2M USD | 10.93M USD | 6.99M USD | 7.67M USD |
| Selling, general, and administrative | 7.7M USD | 13.71M USD | 21.14M USD | 13.07M USD | 8.67M USD |
| Operating expenses | 10.28M USD | 19.91M USD | 32.08M USD | 20.06M USD | 18.12M USD |
| Interest income | 3.18M USD | 5.19M USD | 1.07M USD | 629K USD | — |
| Interest expense | 812K USD | 585K USD | — | — | 67K USD |
| Depreciation and amortization | 210K USD | 246K USD | 238K USD | 256K USD | 775K USD |
| Operating income | −10.53M USD | −19.77M USD | −31.92M USD | −19.92M USD | −18.84M USD |
| Net income | −13.96M USD | −17.32M USD | −28.96M USD | −19.45M USD | −19.13M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 3 ratings. Interpret the distribution with caution.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Feb 10, 2026 | 1,031:1,000 | — | — |
Stock split | Jun 12, 2025 | 1:100 | — | — |
Stock split | Jun 11, 2019 | 1:44 | — | — |
Stock split | Aug 29, 2016 | 1:12 | — | — |
Effective Feb 10, 2026
1,031:1,000
Effective Jun 12, 2025
1:100
Effective Jun 11, 2019
1:44
Effective Aug 29, 2016
1:12
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
